What is Teva Pharmaceutical Industries Revenue per Share?
Teva Pharmaceutical Industries's revenue per share for the
three
months ended in Dec. 2023 was $3.98.
Teva Pharmaceutical Industries's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was $14.12.
Warning Sign:
Teva Pharmaceutical Industries Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Teva Pharmaceutical Industries was 5.30% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -2.40% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -4.60% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was -6.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Teva Pharmaceutical Industries's Revenue per Share or its related term are showing as below:
TEVA'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -12.1 Med: 14.1 Max: 58.5
Current: -2.4
During the past 13 years, Teva Pharmaceutical Industries's highest 3-Year average Revenue Per Share Growth Rate was 58.50% per year. The lowest was -12.10% per year. And the median was 14.10% per year.
TEVA's 3-Year Revenue Growth Rate is ranked worse than 75% of 924
companies
in the Drug Manufacturers industry
Industry Median: 6.4
vs TEVA: -2.40
Teva Pharmaceutical Industries Revenue per Share Historical Data
The historical data trend for Teva Pharmaceutical Industries's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Teva Pharmaceutical Industries Revenue per Share Chart
Competitive Comparison of Teva Pharmaceutical Industries's Revenue per Share
For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teva Pharmaceutical Industries's PS Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's PS Ratio distribution charts can be found below:
* The bar in red indicates where Teva Pharmaceutical Industries's PS Ratio falls into.
Teva Pharmaceutical Industries Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Teva Pharmaceutical Industries's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.12
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teva Pharmaceutical Industries (NYSE:TEVA) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Teva Pharmaceutical Industries Revenue per Share Related Terms
Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TEVA has been successfully added to your 